Wednesday, March 21, 2018
Supporting Men > prostate

#Potential #Therapy #Prostate #Cancer BioXcel Therapeutics’ immuno-oncology candidate BXCL701 was shown to enhance the anti-tumor effects of immune checkpoint inhibitors in prostate models, according to an Oct. 5 poster session at the 24th Annual Prostate Cancer Foundation Scientific Retreat in Washington, D.C. The company reported recent findings from multiple studies showing that BXCL701 — a

Read More